164 related articles for article (PubMed ID: 36951474)
1. Disparities in stage at diagnosis among breast cancer molecular subtypes in China.
Zeng H; Wu S; Ma F; Ji JS; Lu L; Ran X; Shi J; Li D; An L; Zheng R; Zhang S; Chen W; Wei W; He Y; He J
Cancer Med; 2023 May; 12(9):10865-10876. PubMed ID: 36951474
[TBL] [Abstract][Full Text] [Related]
2. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
Chen L; Cook LS; Tang MT; Porter PL; Hill DA; Wiggins CL; Li CI
Breast Cancer Res Treat; 2016 Jun; 157(3):545-54. PubMed ID: 27220749
[TBL] [Abstract][Full Text] [Related]
3. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California.
Parise C; Caggiano V
Cancer Epidemiol; 2014 Oct; 38(5):556-62. PubMed ID: 25172158
[TBL] [Abstract][Full Text] [Related]
4. Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study.
Su Y; Zheng Y; Zheng W; Gu K; Chen Z; Li G; Cai Q; Lu W; Shu XO
BMC Cancer; 2011 Jul; 11():292. PubMed ID: 21749714
[TBL] [Abstract][Full Text] [Related]
5. Association between common risk factors and molecular subtypes in breast cancer patients.
Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
Breast; 2013 Jun; 22(3):344-50. PubMed ID: 22981738
[TBL] [Abstract][Full Text] [Related]
6. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population.
Abubakar M; Sung H; Bcr D; Guida J; Tang TS; Pfeiffer RM; Yang XR
Breast Cancer Res; 2018 Sep; 20(1):114. PubMed ID: 30227867
[TBL] [Abstract][Full Text] [Related]
8. The diverse distribution of risk factors between breast cancer subtypes of ER, PR and HER2: a 10-year retrospective multi-center study in China.
Song Q; Huang R; Li J; Fan J; Zheng S; Zhang B; Yang H; Tang Z; He J; Xie X; Li H; Li J; Qiao Y
PLoS One; 2013; 8(8):e72175. PubMed ID: 23977244
[TBL] [Abstract][Full Text] [Related]
9. Comparison of breast cancer risk factors among molecular subtypes: A case-only study.
Zhang L; Huang Y; Feng Z; Wang X; Li H; Song F; Liu L; Li J; Zheng H; Wang P; Song F; Chen K
Cancer Med; 2019 Apr; 8(4):1882-1892. PubMed ID: 30761775
[TBL] [Abstract][Full Text] [Related]
10. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
[TBL] [Abstract][Full Text] [Related]
11. Epidemiological risk factors associated with inflammatory breast cancer subtypes.
Atkinson RL; El-Zein R; Valero V; Lucci A; Bevers TB; Fouad T; Liao W; Ueno NT; Woodward WA; Brewster AM
Cancer Causes Control; 2016 Mar; 27(3):359-66. PubMed ID: 26797453
[TBL] [Abstract][Full Text] [Related]
12. Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer.
Cespedes Feliciano EM; Kwan ML; Kushi LH; Chen WY; Weltzien EK; Castillo AL; Sweeney C; Bernard PS; Caan BJ
Cancer; 2017 Jul; 123(13):2535-2542. PubMed ID: 28295245
[TBL] [Abstract][Full Text] [Related]
13. Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status.
Chen L; Li CI
Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1666-72. PubMed ID: 26464428
[TBL] [Abstract][Full Text] [Related]
14. Clinical and epidemiologic factors associated with breast cancer and its subtypes among Northeast Chinese women.
Ye DM; Li Q; Yu T; Wang HT; Luo YH; Li WQ
Cancer Med; 2019 Dec; 8(17):7431-7445. PubMed ID: 31642614
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series.
McCormack VA; Joffe M; van den Berg E; Broeze N; Silva Idos S; Romieu I; Jacobson JS; Neugut AI; Schüz J; Cubasch H
Breast Cancer Res; 2013; 15(5):R84. PubMed ID: 24041225
[TBL] [Abstract][Full Text] [Related]
16. Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression.
Kwan ML; Kroenke CH; Sweeney C; Bernard PS; Weltzien EK; Castillo A; Factor RE; Maxfield KS; Stijleman IJ; Kushi LH; Quesenberry CP; Habel LA; Caan BJ
BMC Cancer; 2015 Apr; 15():278. PubMed ID: 25884832
[TBL] [Abstract][Full Text] [Related]
17. Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil.
Carvalho FM; Bacchi LM; Pincerato KM; Van de Rijn M; Bacchi CE
BMC Womens Health; 2014 Aug; 14():102. PubMed ID: 25174527
[TBL] [Abstract][Full Text] [Related]
18. The influence of stage at diagnosis and molecular subtype on breast cancer patient survival: a hospital-based multi-center study.
Zuo T; Zeng H; Li H; Liu S; Yang L; Xia C; Zheng R; Ma F; Liu L; Wang N; Xuan L; Chen W
Chin J Cancer; 2017 Oct; 36(1):84. PubMed ID: 29070080
[TBL] [Abstract][Full Text] [Related]
19. Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014.
Scott LC; Mobley LR; Kuo TM; Il'yasova D
Cancer; 2019 Oct; 125(19):3412-3417. PubMed ID: 31282032
[TBL] [Abstract][Full Text] [Related]
20. The characteristics of breast cancer subtypes: implications for treatment guidelines and individualized treatment strategies in China.
Zheng S; Song QK; Ren Y; Feng WL; Kong YN; Huang R; Xu F; Li J; Zhang BN; Fan JH; He JJ; Qiao YL
Appl Immunohistochem Mol Morphol; 2014; 22(5):383-9. PubMed ID: 24162264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
